108 related articles for article (PubMed ID: 35617640)
1. Economic Cost and Sustainability of Oral Therapies in Precision Oncology.
Desai AP; Scheckel CJ; Soderberg LC; Jensen CJ; Orme JJ; Tella SH; Kommalapati A; Pritchett JC; Khera N; Mahipal A; Go RS;
JCO Oncol Pract; 2022 Aug; 18(8):e1247-e1254. PubMed ID: 35617640
[TBL] [Abstract][Full Text] [Related]
2. Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020.
Desai A; Scheckel C; Jensen CJ; Orme J; Williams C; Shah N; Leventakos K; Adjei AA
JAMA Netw Open; 2022 Jan; 5(1):e2144923. PubMed ID: 35076701
[TBL] [Abstract][Full Text] [Related]
3. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
Li DG; Joyce C; Mostaghimi A
JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
[TBL] [Abstract][Full Text] [Related]
4. Rapid rise in the cost of targeted cancer therapies for Medicare patients with solid tumors from 2006 to 2015.
Wilson LE; Greiner MA; Altomare I; Rotter J; Dinan MA
J Geriatr Oncol; 2021 Apr; 12(3):375-380. PubMed ID: 33250425
[TBL] [Abstract][Full Text] [Related]
5. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
6. The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.
Keating NL; Brooks GA; Landrum MB; Liu PH; Wolf R; Riedel LE; Kapadia NS; Jhatakia S; Tripp A; Simon C; Hsu VD; Kummet CM; Hassol A
J Natl Cancer Inst; 2022 Jun; 114(6):871-877. PubMed ID: 35134972
[TBL] [Abstract][Full Text] [Related]
7. A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer.
Tian C; Wei Y; Li J; Huang Z; Wang Q; Lin Y; Lv X; Chen Y; Fan Y; Sun P; Xiang R; Chang A; Yang S
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35270034
[TBL] [Abstract][Full Text] [Related]
8. The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors.
Seetasith A; Wong W; Tse J; Burudpakdee C
J Med Econ; 2019 May; 22(5):414-420. PubMed ID: 30729850
[TBL] [Abstract][Full Text] [Related]
9. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
Sammons S; Shastry M; Dent S; Anders C; Hamilton E
Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
[TBL] [Abstract][Full Text] [Related]
10. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
Dickson S
JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
[TBL] [Abstract][Full Text] [Related]
11. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
12. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
[TBL] [Abstract][Full Text] [Related]
13. Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.
Albaba H; Lim C; Leighl NB
Pharmacoeconomics; 2017 Dec; 35(12):1195-1209. PubMed ID: 28861770
[TBL] [Abstract][Full Text] [Related]
14. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
[TBL] [Abstract][Full Text] [Related]
15. Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.
Song H; Adamson A; Mostaghimi A
JAMA Dermatol; 2017 Aug; 153(8):755-759. PubMed ID: 28453645
[TBL] [Abstract][Full Text] [Related]
16. Social Security cost-of-living adjustments and the Consumer Price Index.
Burdick C; Fisher L
Soc Secur Bull; 2007; 67(3):73-88. PubMed ID: 18605219
[TBL] [Abstract][Full Text] [Related]
17. Specialty pharmacy services for patients receiving oral medications for solid tumors.
Stein J; Mann J
Am J Health Syst Pharm; 2016 Jun; 73(11):775-96. PubMed ID: 27126828
[TBL] [Abstract][Full Text] [Related]
18. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
[TBL] [Abstract][Full Text] [Related]
20. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
Martin JM; Handorf EA; Montero AJ; Goldstein LJ
Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
